1. Home
  2. IBG vs AIMD Comparison

IBG vs AIMD Comparison

Compare IBG & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

IBG

Innovation Beverage Group Limited Ordinary Shares

HOLD

Current Price

$1.69

Market Cap

8.8M

ML Signal

HOLD

AIMD

Ainos Inc.

HOLD

Current Price

$1.95

Market Cap

10.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
IBG
AIMD
Founded
2018
1984
Country
Australia
United States
Employees
N/A
N/A
Industry
Beverages (Production/Distribution)
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Staples
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.8M
10.2M
IPO Year
2024
N/A

Fundamental Metrics

Financial Performance
Metric
IBG
AIMD
Price
$1.69
$1.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
60.8K
19.6K
Earning Date
05-12-2026
03-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$113,037.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
178.19
52 Week Low
$1.40
$1.61
52 Week High
$9.85
$4.75

Technical Indicators

Market Signals
Indicator
IBG
AIMD
Relative Strength Index (RSI) 37.18 47.86
Support Level $1.50 $1.86
Resistance Level $1.75 $1.97
Average True Range (ATR) 0.16 0.12
MACD -0.01 0.04
Stochastic Oscillator 33.33 87.50

Price Performance

Historical Comparison
IBG
AIMD

About IBG Innovation Beverage Group Limited Ordinary Shares

Innovation Beverage Group Ltd is a developer, manufacturer, marketer, exporter, and retailer of a growing beverage portfolio of 70 formulations across 14 alcoholic and non-alcoholic brands. The company's focus is on premium and super premium brands. The Group has two reportable geographic segments: Australia and the United States.

About AIMD Ainos Inc.

Ainos Inc is a dual-platform AI and biotech company pioneering smelltech and immune therapeutics. Its AI Nose platform and smell language model (SLM) digitize scent into Smell ID, a machine-readable data format, powering intelligent sensing across robotics, smart factories, and healthcare. The company also develops VELDONA, a low-dose oral interferon targeting rare, autoimmune, and infectious diseases. It combines AI and Nose, redefining machine perception for the sensory age.

Share on Social Networks: